Medpace Holdings, Inc. $MEDP is Riverbridge Partners LLC's 9th Largest Position

Key Points

• Riverbridge Partners LLC has reduced its stake in Medpace Holdings, Inc. by 9.8%, making it the firm's 9th largest position in their investment portfolio.
• Medpace reported Q2 earnings of $3.10 per share, exceeding the consensus estimate by $0.10, and had a year-over-year revenue increase of 14.2%.
• Analysts have mixed ratings on Medpace, with the current consensus rating being "Reduce" and target prices ranging from $400.00 to $490.00.

Riverbridge Partners LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 9.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 434,024 shares of the company's stock after selling 47,102 shares during the quarter. Medpace accounts for approximately 2.2% of Riverbridge Partners LLC's investment portfolio, making the stock its 9th largest position. Riverbridge Partners LLC owned 1.51% of Medpace worth $136,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after buying an additional 83 shares during the period. Inspire Investing LLC purchased a new position in Medpace during the first quarter worth $2,059,000. Voya Investment Management LLC boosted its stake in Medpace by 7.6% during the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company's stock worth $6,696,000 after buying an additional 1,560 shares during the period. Zeno Equity Partners LLP boosted its stake in Medpace by 2.6% during the first quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company's stock worth $18,983,000 after buying an additional 1,564 shares during the period. Finally, United Services Automobile Association purchased a new position in Medpace during the first quarter worth $500,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on MEDP shares. Rothschild Redb downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Robert W. Baird lifted their target price on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research report on Tuesday, September 9th. Finally, Zacks Research downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of "Reduce" and a consensus target price of $422.27.

Medpace Price Performance

MEDP stock opened at $497.32 on Thursday. The business has a 50-day moving average price of $457.76 and a 200 day moving average price of $358.54. The company has a market capitalization of $13.97 billion, a P/E ratio of 36.98, a PEG ratio of 3.12 and a beta of 1.44. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm's quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the transaction, the chief executive officer directly owned 925,799 shares in the company, valued at approximately $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock valued at $74,111,427 over the last three months. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.